Nkarta Inc
NASDAQ:NKTX

Watchlist Manager
Nkarta Inc Logo
Nkarta Inc
NASDAQ:NKTX
Watchlist
Price: 2.41 USD -0.41% Market Closed
Market Cap: 170.1m USD
Have any thoughts about
Nkarta Inc?
Write Note

Net Margin
Nkarta Inc

0%
Current
0%
Average
-7.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-110.6m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Nkarta Inc
NASDAQ:NKTX
170.8m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.6B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.2B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
136.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
Country US
Market Cap 170.8m USD
Net Margin N/A
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 314.6B USD
Net Margin
9%
Country US
Market Cap 141.2B USD
Net Margin
13%
Country US
Market Cap 117.2B USD
Net Margin
0%
Country US
Market Cap 105.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 136.4B AUD
Net Margin
18%
Country US
Market Cap 78.4B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Nkarta Inc
Glance View

Market Cap
170.1m USD
Industry
Biotechnology

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 136 full-time employees. The company went IPO on 2020-07-10. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety and a membrane-bound form of the cytokine IL15 (mbIL-15). The Company’s co-lead product candidates are NKX101 and NKX019. NKX101 is designed to innate NK biology to detect and kill cancerous cells. The primary activating receptor for NK cells is known as NKG2D, which works through the detection of stress ligands displayed by cancerous cells. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells for understanding NK cell biology.

NKTX Intrinsic Value
Not Available

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-110.6m
/
Revenue
0
What is the Net Margin of Nkarta Inc?

Based on Nkarta Inc's most recent financial statements, the company has Net Margin of 0%.